Efficacy and Safety of Lenvatinib Plus Everolimus in Metastatic Renal Cell Carcinoma after Immune Checkpoint and VEGFR Tyrosine Kinase Inhibitors Treatment
Cancer Research and Treatment · 2026
DOI: 10.4143/crt.2025.628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2026. Verfasst von So Heun Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Phenylurea Compounds, Everolimus, Quinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Real-world data on the efficacy and safety of lenvatinib plus everolimus in metastatic renal cell carcinoma (RCC) after failure of immune checkpoint inhibitors (ICIs) and/or vascular endothelial growth factor receptor (VEGFR)–targeted tyrosine kinase inhibitors (TKIs) remain limited.Materials and Methods This single-center retrospective study included patients with metastatic RCC treated with lenvatinib plus everolimus as second-line or later therapy at Asan Medical Center, Korea, between September 2017 and June 2024. Data on dose adjustments, treatment response, survival, and adverse events were collected from electronic medical records. Primary endpoints were objective response rate (ORR) and progression-free survival (PFS); secondary endpoints included overall survival (OS), time to progression, adverse events, and prognostic factors.
Results
A total of 83 patients were included, predominantly with clear cell histology (90.4%). The median number of prior therapies was four (range, 1 to 7), with 80.7% receiving the combination as fourth-line or beyond. All had prior anti-angiogenic TKI exposure, 86.7% had received ICIs, and 37.3% had prior mTOR inhibitor therapy. The ORR was 40.0%, with disease control at 81.3%. Median PFS and OS were 5.4 months (95% confidence intervals [CI], 4.4 to 6.8) and 8.5 months (95% CI, 6.3 to 12.1), respectively. Efficacy was consistent across key subgroups. During the treatment, lenvatinib dose reductions were required in 55.4% of patients, and 26.5% experienced treatment interruptions. Grade ≥ 3 proteinuria occurred in 22.9%.
Conclusion
Lenvatinib plus everolimus demonstrated promising efficacy in heavily pretreated patients with metastatic RCC, including those previously exposed to VEGFR-targeted TKIs and/or ICIs. Further studies are warranted to optimize treatment strategies in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jaelyun@amc.seoul.kr.
Zitieren
APA
Lee, S. H., Park, I., Yoon, S., & Lee, J. L. (2026). Efficacy and Safety of Lenvatinib Plus Everolimus in Metastatic Renal Cell Carcinoma after Immune Checkpoint and VEGFR Tyrosine Kinase Inhibitors Treatment. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.628
Vancouver
Lee SH, Park I, Yoon S, Lee JL. Efficacy and Safety of Lenvatinib Plus Everolimus in Metastatic Renal Cell Carcinoma after Immune Checkpoint and VEGFR Tyrosine Kinase Inhibitors Treatment. Cancer Research and Treatment. 2026. doi:10.4143/crt.2025.628
BibTeX
@article{Lee2026,
author = {Lee, So Heun and Park, Inkeun and Yoon, Shinkyo and Lee, Jae Lyun},
title = {Efficacy and Safety of Lenvatinib Plus Everolimus in Metastatic Renal Cell Carcinoma after Immune Checkpoint and VEGFR Tyrosine Kinase Inhibitors Treatment},
journal = {Cancer Research and Treatment},
year = {2026},
doi = {10.4143/crt.2025.628}
}
EUVIMED